UTHR - Company ID 0001082554
The table below shows UNITED THERAPEUTICS Corp's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B | $1.48B |
| Cost of revenue | $384.40M | $309.70M | $257.50M | $151.60M | $122.50M | $108.10M |
| Gross profit | $2.80B | $2.57B | $2.07B | $1.78B | $1.56B | $1.38B |
| R&D | $550.00M | $481.00M | $408.00M | $322.90M | $540.10M | $357.70M |
UNITED THERAPEUTICS Corp reported annual revenue of $3.18B for fiscal year 2025. That is up 10.6% from $2.88B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.60B (FY 2016) to $3.18B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $755.80M |
| $709.70M |
| $477.10M |
| $482.10M |
| $467.00M |
| - |
| Operating income | $1.49B | $1.38B | $1.18B | $979.70M | $555.90M | $593.60M |
| Income tax | $379.20M | $343.90M | $289.50M | $223.30M | $118.10M | $124.10M |
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | $475.80M | - |
| EPS (diluted) | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 |